Teplizumab in adults & children with recent onset diabetes

• Research type

  Research Study

• Full title

  A Phase 3, Randomised, Double-Blind, Multinational, Placebo-Controlled Study to Evaluate Efficacy and Safety of Teplizumab (MGA031), a Humanised, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Children and Adults with Recent-Onset Type 1 Diabetes Mellitus

• IRAS ID

  25206

• Contact name

  John Wilding

• Contact email

  J.P.H.Wilding@liverpool.ac.uk

• Sponsor organisation

  MacroGenics, Inc.

• Eudract number

  2009-011606-41

• Clinicaltrials.gov Identifier

  NCT00920582

• Research summary

  Research Summary not published at request of researcher

• REC name

  South Central - Oxford B Research Ethics Committee

• REC reference

  09/H0605/104

• Date of REC Opinion

  6 Nov 2009

• REC opinion

  Further Information Favourable Opinion